Spectrum of Viruses and Atypical Bacteria in Intercontinental Air Travelers with Symptoms of Acute Respiratory Infection

Luciano Kleber de Souza Luna, Marcus Panning, Klaus Grywna, Susanne Pfefferle, and Christian Drosten
Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany

(See the editorial commentary by Pavia, on pages 621–2.)

Respiratory infections after air travel are frequent, but epidemiological data are incomplete. Using sensitive polymerase chain reactions, we studied the spectrum of atypical bacteria and respiratory viruses in travelers fulfilling the case definition of severe acute respiratory syndrome. A pathogen was identified in 67 travelers (43.2%). Influenza and parainfluenza viruses were most prevalent, at 14.2% and 15.5%, respectively. Prevalences of adenoviruses, human metapneumovirus, coronaviruses, and rhinoviruses ranged between 2.6% and 4.8%. Human bocavirus, respiratory syncytial virus, and Legionella, Mycoplasma, and Chlamydia species were absent or appeared at frequencies of <1%. To our knowledge, these are the first specific baseline data for the mentioned agents in the context of air travel.

Acute respiratory infections are frequently experienced after air travel. Because most patients do not see a doctor, current knowledge about incidence and etiology is imprecise and anecdotal [1]. The very few systematic studies available suggested that up to 20% of passengers may develop respiratory infections within 1 week after air travel and that flight attendants show evidence of respiratory distress syndrome without other reason. The very few systematic studies available suggested that up to 20% of passengers may develop respiratory infections within 1 week after air travel and that flight attendants show evidence of respiratory distress syndrome without other reason. Even though antibiotic therapy may significantly reduce symptom severity, it does not prevent the occurrence of infections.

After initial characterization of the causative agent of SARS, we acted as a diagnostic reference laboratory for the World Health Organization (WHO) [6]. During the epidemic, we accepted samples for initial and confirmatory testing exclusively from those patients who fulfilled the WHO case definition of suspected or probable SARS. The definition was designed to be sensitive and thus to prevent any possible transmission, but its specificity was low. It covered most respiratory illnesses compatible with viral or atypical bacterial infection.

Respiratory agents are best diagnosed by direct assays, the most sensitive of which is polymerase chain reaction (PCR). Because of the rapid pace at which the technique evolves, we searched the literature for the most up-to-date PCR assays that cover the broadest possible range of genetic diversity for each respective agent. High sensitivities had to be clearly proved in studies. Where assays fulfilling these criteria were not available, we established sensitive real-time PCRs de novo. These assays were used to determine a point prevalence of the full spectrum of respiratory viruses and atypical bacteria in SARS-compatible patients.

Patients and methods. Respiratory samples (n = 214) from 172 patients were available. All patients fulfilled the WHO case definition of suspected or probable SARS, which required a combination of fever and lower-respiratory-tract symptoms (e.g., cough or difficulty breathing) plus either a stay in an affected area during the preceding 10 days or close contact with suspected patients. Probable cases additionally had radiological evidence of respiratory distress syndrome without other reason.

Samples were prepared as described elsewhere [6]. Assays included adenovirus (AdV) [7]; rhinovirus (RV) [8]; human bocavirus (hBoV) [9]; human coronaviruses (hCoV) 229E, NL63, and OC43 (table 1); influenza virus (Inf) A (table 1); and a combined assay for Inf A and B, parainfluenzaviruses (PIVs) 1–3, respiratory syncytial virus (RSV), and human metapneumovirus (hMPV) (Hexaplex Plus; Prodesse). The commercial system was chosen because several published respiratory multiplex assays gave instable results in our laboratory. We also tested for the presence of atypical bacteria, including Mycoplasma, Chlamydia, and Legionella species [10]. For-
### Table 1. Formulations of reverse-transcription (RT)–polymerase chain reaction (PCR) assays designed for the study.

<table>
<thead>
<tr>
<th>Virus</th>
<th>Sense primer</th>
<th>Probe</th>
<th>Antisense primer</th>
<th>Formulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>hCoV 229E and OC43</td>
<td>tactatgactgagcagttcga and tactatgactaataacagttcga, 1:1 mixture of both oligonucleotides (200 nmol/L each)</td>
<td>Anchor probe, gtgttcctgttagttaggacactaa-FL and atgcacccgtttagcagcactaa-FL, 1:1 mixture of both oligonucleotides (20 nmol/L each); detector probe, LCred640-tttatgtggttggactatagtgt-P (40 nmol/L)</td>
<td>ggcatacgaacacacttttg (400 nmol/L)</td>
<td>Dual-probe real-time PCR, Roche Light Cycler; Promega Access 1-step RT-PCR system. Reaction volume 25 µL, RNA input volume 5 µL; 1× Promega Access reaction buffer, 200 mmol/L dNTP, 1 mmol/L magnesium sulfate, and 0.8 µg bovine serum albumin; 30 min at 42°C, 2 min at 94°C, 45 cycles of 5 s at 94°C, 10 s at 50°C, and 20 s at 72°C. End-point detection by melting-curve analysis.</td>
</tr>
<tr>
<td>hCoV NL63</td>
<td>aaacctccgtggagcgtg (400 nmol/L)</td>
<td>FL-atgtacctccgctttctcgtgctg-Tamra (400 nmol/L)</td>
<td>ctgtaaacccctttggcatc (200 nmol/L)</td>
<td>5′-nuclease PCR, Invitrogen Superscript/Platinum system, Roche Light Cycler; reaction volume 25 µL, RNA input volume 5 µL; 1× Superscript/Platinum reaction mix, additional 2 mmol/L magnesium sulfate, and 0.8 µg bovine serum albumin; 20 min at 45°C, 5 min at 99°C, 45 cycles of 5 s at 99°C and 30 s at 58°C. Real-time detection.</td>
</tr>
<tr>
<td>Inf A&lt;sup&gt;a&lt;/sup&gt;</td>
<td>gatgagctccttcaacgcagttcg (600 nmol/L)</td>
<td>FL-tcaggccccctaaacgccag-Tamra (200 nmol/L)</td>
<td>tggaaacacatctcagtccttg (600 nmol/L)</td>
<td>5′-nuclease PCR, Invitrogen Superscript/Platinum system, 7700 SDS; reaction volume 25 µL, RNA input volume 5 µL; 1× Superscript/Platinum reaction mix, additional 3 mmol/L magnesium sulfate, and 0.8 µg bovine serum albumin; 20 min at 45°C, 5 min at 99°C, 45 cycles of 15 s at 99°C and 36 s at 58°C. Real-time detection.</td>
</tr>
</tbody>
</table>

**NOTE.** All oligonucleotides were synthesized by TibMolbiol, Berlin, Germany. FL, fluorescein; hCoV, human coronavirus; Inf, influenza virus; LCred640, LightCycler red 640; P, phosphate.

<sup>a</sup> This assay was used in addition to the Prodesse Hexaplex system. All results were congruent between assays.
Figure 1. A, Age distribution of patients (left) and rates of detection of any tested agent in 4 different age groups (middle and right). The age of 15 of 172 patients could not be recorded because these were coded requests forwarded to us by other laboratories. Range lines in the middle and right panels depict 95% confidence intervals (CIs). Note that large CIs in the contacts panel are due to the small no. of patients in this group (n = 17). Sample sizes in the different age groups were as follows. In the middle panel (flight patients), 1–18 years, 8 patients; 19–35 years, 37 patients; 36–60 years, 64 patients; and 61–79 years, 31 patients. In the right panel (contact patients), 1–18 years, 1 patient; 19–35 years, 5 patients; 36–60 years, 8 patients; and 61–79 years, 3 patients. B, Relative detection rates of agents in travelers. AdV, adenovirus; BoV, bocavirus; hCoV, human coronavirus; hMPV, human metapneumovirus; hPIV, human parainfluenza virus; Inf, influenza virus; RSV, respiratory syncytial virus; RV, rhinovirus.

Results. Travel histories were reconstructed by telephone interviews with hospitals, family physicians, or patients themselves. For 164 patients (hereafter called “flight patients”), additional information was retrieved. This included 124 for whom the exact dates and destinations of departure to Germany were known and 22 for whom only destinations could be reconstructed. Seventeen patients had not traveled as initially reported but had been in contact with patients who had suspected SARS. For 8 patients, no additional information could be retrieved. They were included in the cohort because a travel history had been confirmed before samples were received. Only those patients who had reportedly not traveled were evaluated separately. They are hereafter called “contact patients.”

The average age of flight patients was 42.2 years (range, 1–79 years). The average age of contact patients was 41.8 years (range, 4–79 years). Neither the average or median ages nor the SDs in both groups were significantly different. Figure 1 shows the age distributions in both groups. Some 71% of flight patients were between 19 and 60 years old, as were 76% of contact patients (P = .57). Only 12 patients were <19 years old, 11 of whom were flight patients. They contributed 13.4% of all positive findings in flight patients, which was significantly more than the mean positivity rate in all age groups (P < .012, Student’s t test).

At least 1 pathogen was detected in 67 flight patients (43.2%)
and in 8 contact patients (47%) (P = .7, Student’s t test). Table 2 shows the global pathogen detection rates by age group, as well as the relative and absolute prevalences of pathogens in flight patients. In contact patients (n = 17), AdV, human PIV, Inf B, and hMPV were detected in 2 patients each and Inf A in 1 patient. Double infections occurred in only 2 patients: RV/PIV in a flight patient and AdV/PIV in a contact patient.

Inf and PIV were clearly the most prevalent agents in flight patients, at 14.2% and 15.5%, respectively, without significant differences between age groups (1-way analysis of variance [ANOVA], 95% significance level). Equal distribution of these viruses was also seen in contact patients. CoVs were more frequent than one would expect in a mostly adult cohort. Detection rates did not differ between age groups at the 95% significance level. RSV and hMPV appeared to be significantly more frequent in flight patients <18 years old than in the other age groups (P = .006 and .01, F test). For hMPV, this was also seen in contact patients (P = .02, F test). The novel hBoV was not detected in any patient, which indicates that this agent may be restricted to children. Indeed, all data available so far about BoV have been derived from cohorts of young infants [9, 11, 12]. A complete absence was also observed of Chlamydophila species, but it cannot be derived from our data what fraction of patients had already received preemptive antibiotic treatment at the time of sampling.

Flight destinations were analyzed next. Destinations of departure to Germany included Beijing (n = 24), Hong Kong (n = 19), Bangkok (n = 17), Shanghai (n = 14), Hanoi (n = 13), Singapore (n = 13), Toronto (n = 6), Taiwan (n = 3), and Kuala Lumpur (n = 2); single patients traveled from other airports in China, Southeast Asia, and the United States. Flights were distributed over 69 different days. For 12 of 146 flights evaluated, there was at least 1 other patient who had departed from the same city on the same day. Because flight numbers were not available, results from all patients (n = 25) who had traveled on nonunique flight dates were compared. Only in 2 cases did 2 patients have the same diagnosis (hPIV in both).

There was no association between the airport of departure and the detection of pathogens in general (P < .3, 1-way ANOVA) or of any pathogen in particular.

To identify any possible influence of sampling on detection rates, we analyzed common categories of clinical samples separately for both flight and contact patients. Samples were categorized as follows: upper-respiratory-tract samples (category 1), throat-wash fluids (category 2), and lower-respiratory-tract samples (sputum and bronchoalveolar lavage [BAL] fluids; category 3). A comparison of age versus sample type yielded a significant lack of lower-respiratory-tract samples in patients <19 years old (1-way ANOVA, 95% significance level). Because a significantly higher detection rate of viruses had been identified in these patients, they were eliminated from the analysis, to avoid a bias. After elimination, no significant age differences in the 3 categories of samples remained (P = .3, F test). The average ages for categories 1, 2, and 3 were 42.1, 43.9, and 47.0 years, respectively.

Upper-respiratory-tract samples analyzed included 39 pharyngeal, nasal, and nasopharyngeal swabs and 99 throat-wash fluids. Lower-respiratory-tract samples included 50 sputum specimens and 4 BAL fluids. The detection frequencies of every pathogen in the 3 categories were compared by separate ANOVAs. Global detection frequencies did not differ significantly between categories (any pathogen: 51.3%, 34.3%, and 46.3% in category 1, 2, and 3, respectively). Only for Inf was the detection frequency in swabs was significantly higher than that for other samples (category 1, 30.1%; category 2, 10.1%; category 3, 14.8%; P = .01, F test). The same was observed for Inf A only (21%, 5%, and 9%, respectively; P = .01) but not for Inf B alone.

**Discussion.** Baseline data on the prevalence of respiratory viruses and atypical bacteria after air travel are not currently available. These patients constitute a specific subcohort of patients with community-acquired respiratory disease. Unlike general cohorts, children and elderly persons are underrepresented, and adults of working age constitute the majority of patients (71% in our study). Normally, respiratory infections in adults are mild and infrequent, but this may change in the context of travel. There is evidence that air travel increases the incidence of respiratory disease in general and that significant transmission in modern aircraft has occurred of SARS, Inf, and other agents of respiratory infection [2, 4]. Because morbidity during working life is economically relevant and new thera-

<table>
<thead>
<tr>
<th>Agent</th>
<th>Detection rate, no. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>hPIV</td>
<td>24 (15.5)</td>
</tr>
<tr>
<td>Inf A</td>
<td>11 (7.1)</td>
</tr>
<tr>
<td>Inf B</td>
<td>11 (7.1)</td>
</tr>
<tr>
<td>AdV</td>
<td>6 (3.9)</td>
</tr>
<tr>
<td>hCoV OC43/HKU-1</td>
<td>5 (3.2)</td>
</tr>
<tr>
<td>hCoV 229E</td>
<td>0</td>
</tr>
<tr>
<td>hCoV NL63</td>
<td>0</td>
</tr>
<tr>
<td>RV</td>
<td>4 (2.6)</td>
</tr>
<tr>
<td>hMPV</td>
<td>4 (2.6)</td>
</tr>
<tr>
<td>RSV</td>
<td>1 (0.6)</td>
</tr>
<tr>
<td>BoV</td>
<td>0</td>
</tr>
<tr>
<td>Mycoplasma species</td>
<td>1 (0.6)</td>
</tr>
<tr>
<td>Legionella species</td>
<td>1 (0.6)</td>
</tr>
<tr>
<td>Chlamydophila species</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>68 (43.8)</td>
</tr>
</tbody>
</table>

**Table 2. Absolute detection rates of agents in flight patients.**

**NOTE.** AdV, adenovirus; BoV, bocavirus; hCoV, human coronavirus; hMPV, human metapneumovirus; hPIV, human parainfluenza virus; Inf, influenza virus; RSV, respiratory syncytial virus; RV, rhinovirus.
ruses in adult respiratory disease will be of growing importance standing the spectrum and the etiological contribution of vi-
spiratory viruses in adults must be carefully studied. Under-
the prevalence of known, emerging, and potentially novel re-

in flight. In any case, data from this unique cohort suggest that are picked up during prior travel rather than being acquired
egen and a particular airport. It would thus be likely that viruses
exist. Similarly, no association was detected between any path-
diagnosis, who could have been on the same flight, did not

ating that significant clusters of patients with the same
diagnosis, who could have been on the same flight, did not exist. Similarly, no association was detected between any path-
gen and a particular airport. It would thus be likely that viruses
are picked up during prior travel rather than being acquired in flight. In any case, data from this unique cohort suggest that the prevalence of known, emerging, and potentially novel respiratory viruses in adults must be carefully studied. Understanding the spectrum and the etiological contribution of viruses in adult respiratory disease will be of growing importance in the future. With new antiviral drugs at hand, more consultations will occur for respiratory diseases. Targeted therapy will require broad-spectrum pathogen detection with rapid results, most likely by PCR. Given the large range of assays required for this study and considering current reagent costs, it is obvious that developing more efficient diagnostic assays is as essential as developing drugs themselves. Today, diagnostic technology is far from attaining this aim.

Acknowledgments

We are grateful to Laurent Kaiser, Eric Claas, and Harald Kessler for providing detailed bench protocols for the published polymerase chain reaction assays used in the study.

References


8. Deffnerz C, Wunderli W, Thomas Y, Yerly S, Perrin L, Kaiser L. Am-